Abstract

Direct Healthcare Professional Communication (DHPC) is essentially distributed for fast communication of new serious drug safety information to healthcare professionals (HCPs). However, the use of this tool concerning the knowledge and preferences of HCPs has never been evaluated in Egypt. This study aimed to evaluate the HCPs' knowledge, preferences, and barriers to the use of DHPC in Egypt. A cross-sectional study of a random sample of 254 HCPs surveyed via face-to-face interviews to assess the Egyptian HCPs' awareness of DHPC, the preferences, and barriers that affect its use. Among the 297 approached HCPs, only 254 accepted to participate with a response rate of 85.5%, including (50% internists, 22.83% cardiologists, 11.02% neurologists, 11.02% pediatricians, and 5.12% from other specialties). Most HCPs were not familiar with DHPC (N= 254, 61.8%). One-third of the visited HCPs who were aware of concerned drugs' risk(s) got their information from DHPC (N= 149, 36.9%). HCPs preference for communication channel was highest for meetings (N= 254, 65.7%) and least for newsletters (N= 254, 28%). HCPs reported barriers to reading DHPC included; busy schedule (N= 254, 47.6%), mistrusted source (N= 254, 24.4%), view as a marketing tool (N= 254, 21.7%), invaluable information (N= 254, 9.8%) and disbelief (N= 254, 7.5%). The DHPC did not reach the target HCPs most of the time, but when received, it was successful in conveying the required message to the target HCPs. Multiple barriers were identified that negatively impacted the success of DHPC. It is recommended to use other electronic communication methods to enhance the reachability of the current method (DHPC).

Highlights

  • For any medicinal product to be authorized, its benefits should outweigh its risks in the specified indication(s) [1]

  • In certain cases when a serious safety issue is raised necessitating immediate dissemination of information, Direct Health Care Professional Communication (DHPC) distribution can be requested from the related pharmaceutical company [1]

  • Around 297 Egyptian Health Care Professionals (HCPs) were visited for the survey conduction

Read more

Summary

Introduction

For any medicinal product to be authorized, its benefits should outweigh its risks in the specified indication(s) [1]. Pharmacovigilance starts during clinical trials and continues after the drug is released into the market. Due to the various limitations, the complete benefit-risk profile of new drugs can never be achieved through the pre-approval phase of clinical trials, so, with the large scale use of a drug in real life, new serious safety issues may be raised [2]. Pharmaceutical companies should continuously monitor their medicinal product’s safety and inform the health authority of any changes in the known drug safety profile that might affect the risk-benefit balance of the product, and affirm that the product information always remains updated [3]. In certain cases when a serious safety issue is raised necessitating immediate dissemination of information, Direct Health Care Professional Communication (DHPC) distribution can be requested from the related pharmaceutical company [1]. DHPCs are mainly used to communicate urgent new serious safety information to the target Health Care Professionals (HCPs) on time [4]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call